Although the relative risk reduction observed in the study is notable, said Shikha Jain, MD, a board-certified oncologist and hematologist at UI Health and the University of Illinois Cancer Center in Chicago, these results should be interpreted with caution and not prompt changes in colorectal cancer screening recommendations or lead clinicians to prescribe GLP-1s solely for cancer prevention.
You can read the article here: MedCentral